JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

First published online August 17, 2007
J Nucl Med 2007, doi:10.2967/jnumed.106.037689
 © 2007 by Society of Nuclear Medicine
This Article
Right arrow Full Text (Publish Ahead of Print[PDF])
Right arrow All Versions of this Article:
jnumed.106.037689v1
48/9/1468    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, W.

Clinical Applications of PET in Brain Tumors

Wei Chen 1*

1 Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; Department of Radiology, Kaiser Permanente Woodland Hills Medical Center, Woodland Hills, California

* To whom correspondence should be addressed. E-mail: weichen{at}mednet.ucla.edu.


  Abstract

Malignant gliomas and metastatic tumors are the most common brain tumors. Neuroimaging plays a significant role clinically. In low-grade tumors, neuroimaging is needed to evaluate recurrent disease and to monitor anaplastic transformation into high-grade tumors. In high-grade and metastatic tumors, the imaging challenge is to distinguish between recurrent tumor and treatment-induced changes such as radiation necrosis. The current clinical gold standard, MRI, provides superior structural detail but poor specificity in identifying viable tumors in brain treated with surgery, radiation, or chemotherapy. 18F-FDG PET identifies anaplastic transformation and has prognostic value. The sensitivity and specificity of 18F-FDG in evaluating recurrent tumor and treatment-induced changes can be improved significantly by coregistration with MRI and potentially by delayed imaging 3–8 h after injection. Amino acid PET tracers are more sensitive than 18F-FDG in imaging recurrent tumors and in particular recurrent low-grade tumors. They are also promising in differentiating between recurrent tumors and treatment-induced changes.

Key Words: neurology, oncology, PET, brain, tumors




This article has been cited by other articles:


Home page
 NEJMHome page
P. Y. Wen and S. Kesari
Malignant Gliomas in Adults
N. Engl. J. Med., July 31, 2008; 359(5): 492 - 507.
[Full Text] [PDF]

Home page
 JNMHome page
Y. Terakawa, N. Tsuyuguchi, Y. Iwai, K. Yamanaka, S. Higashiyama, T. Takami, and K. Ohata
Diagnostic Accuracy of 11C-Methionine PET for Differentiation of Recurrent Brain Tumors from Radiation Necrosis After Radiotherapy
J. Nucl. Med., May 1, 2008; 49(5): 694 - 699.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
A. A. Brandes, A. Tosoni, F. Spagnolli, G. Frezza, M. Leonardi, F. Calbucci, and E. Franceschi
Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology
Neuro-oncol, January 1, 2008; 10(3): 361 - 367.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2007 by the Society of Nuclear Medicine.